Comorbidities complicating heart failure: changes over the last 15 years.
Comorbidities
Heart failure
Hospitalization
Mortality
Obesity
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
11
05
2022
accepted:
27
07
2022
pubmed:
18
8
2022
medline:
21
1
2023
entrez:
17
8
2022
Statut:
ppublish
Résumé
Management of comorbidities represents a critical step in optimal treatment of heart failure (HF) patients. However, minimal attention has been paid whether comorbidity burden and their prognostic value changes over time. Therefore, we examined the association between comorbidities and clinical outcomes in HF patients between 2002 and 2017. The 2002-HF cohort consisted of patients from The Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) trial (n = 1,032). The 2017-HF cohort were outpatient HF patients enrolled after hospitalization for HF in a tertiary referral academic hospital (n = 382). Kaplan meier and cox regression analyses were used to assess the association of comorbidities with HF hospitalization and all-cause mortality. Patients from the 2017-cohort were more likely to be classified as HF with preserved ejection fraction (24 vs 15%, p < 0.001), compared to patients from the 2002-cohort. Comorbidity burden was comparable between both cohorts (mean of 3.9 comorbidities per patient) and substantially increased with age. Higher comorbidity burden was significantly associated with a comparable increased risk for HF hospitalization and all-cause mortality (HR 1.12 [1.02-1.22] and HR 1.18 [1.05-1.32]), in the 2002- and 2017-cohort respectively. When assessing individual comorbidities, obesity yielded a statistically higher prognostic effect on outcome in the 2017-cohort compared to the 2002-HF cohort (p for interaction 0.026). Despite major advances in HF treatment over the past decades, comorbidity burden remains high in HF and influences outcome to a large extent. Obesity emerges as a prominent comorbidity, and efforts should be made for prevention and treatment. Created with BioRender.com.
Identifiants
pubmed: 35976430
doi: 10.1007/s00392-022-02076-1
pii: 10.1007/s00392-022-02076-1
pmc: PMC9849176
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-133Subventions
Organisme : Hartstichting
ID : CVON SHE-PREDICTS-HF
Organisme : Hartstichting
ID : grant 2017-21
Organisme : Hartstichting
ID : CVON RED-CVD
Organisme : Hartstichting
ID : grant 2017-11
Organisme : Hartstichting
ID : CVON PREDICT2
Organisme : Hartstichting
ID : grant 2018-30
Organisme : Hartstichting
ID : CVON DOUBLE DOSE
Organisme : Hartstichting
ID : grant 2020B005
Organisme : Hartstichting
ID : grant 2000Z003
Organisme : Hartstichting
ID : Dekker grant 03-005-2021-T005
Organisme : Fondation Leducq
ID : Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)
Organisme : H2020 European Research Council
ID : ERC CoG 818715
Organisme : H2020 European Research Council
ID : SECRETE-HF
Organisme : Universitair Medisch Centrum Groningen
ID : Mandema-Stipendium of the Junior Scientific Masterclass 2020-10
Informations de copyright
© 2022. The Author(s).
Références
J Am Coll Cardiol. 2003 Oct 1;42(7):1226-33
pubmed: 14522486
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
ESC Heart Fail. 2018 Apr;5(2):271-278
pubmed: 29265710
Eur Heart J. 2001 Sep;22(17):1527-60
pubmed: 11492984
PLoS Med. 2018 Mar 27;15(3):e1002540
pubmed: 29584734
ESC Heart Fail. 2021 Aug;8(4):2458-2466
pubmed: 34085774
Heart. 2021 Sep;107(17):1417-1421
pubmed: 33153996
PLoS Med. 2018 Mar 27;15(3):e1002541
pubmed: 29584721
Am J Med. 2015 Jan;128(1):38-45
pubmed: 25220613
Eur J Heart Fail. 2004 Mar 1;6(2):227-33
pubmed: 14984731
Eur J Heart Fail. 2020 Jun;22(6):1022-1031
pubmed: 32212297
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2014 Jan;16(1):103-11
pubmed: 24453099
Circulation. 2012 Jul 3;126(1):65-75
pubmed: 22615345
N Engl J Med. 2016 Dec 15;375(24):2349-2358
pubmed: 27959714
Eur J Heart Fail. 2020 Jun;22(6):1032-1042
pubmed: 32293090
Circ Heart Fail. 2018 Jun;11(6):e004646
pubmed: 29793934
Circ Heart Fail. 2015 Jan;8(1):33-40
pubmed: 25399909
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Eur J Heart Fail. 2012 Feb;14(2):168-75
pubmed: 22158778
J Am Coll Cardiol. 2017 Dec 5;70(22):2739-2749
pubmed: 29191321
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
Arch Intern Med. 2008 Feb 11;168(3):316-24
pubmed: 18268174
Am J Ther. 2018 Jul/Aug;25(4):e475-e486
pubmed: 29985826
Expert Opin Pharmacother. 2017 May;18(7):645-655
pubmed: 28375036
JACC Heart Fail. 2017 Apr;5(4):305-309
pubmed: 28359417
Lancet. 2020 Jul 11;396(10244):121-128
pubmed: 32446323
Clin Res Cardiol. 2019 Sep;108(9):1025-1033
pubmed: 30788622
Int J Cardiol. 2017 Dec 1;248:382-388
pubmed: 28712563
Arch Intern Med. 2002 Nov 11;162(20):2269-76
pubmed: 12418941
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
Eur Heart J. 2019 Jul 1;40(26):2131-2138
pubmed: 31089682